Business Description
Vivoryon Therapeutics NV
ISIN : NL00150002Q7
Compare
Compare
Traded in other countries / regions
VVY.Netherlands05Y.Germany0R3M.UK IPO Date
2014-10-27Description
Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products include PQ912 and PQ1565. Geographically, the majority is from Greater China.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 497.44 | |||||
| Equity-to-Asset | 0.92 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -27.7 | |||||
| 3-Year EPS without NRI Growth Rate | -27.3 | |||||
| 3-Year FCF Growth Rate | -2.1 | |||||
| 3-Year Book Growth Rate | -19.8 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.13 | |||||
| 9-Day RSI | 39.38 | |||||
| 14-Day RSI | 22.46 | |||||
| 6-1 Month Momentum % | -92.91 | |||||
| 12-1 Month Momentum % | -95.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 19.45 | |||||
| Quick Ratio | 19.45 | |||||
| Cash Ratio | 18.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.5 | |||||
| Shareholder Yield % | -343.93 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -84.55 | |||||
| ROA % | -72.7 | |||||
| ROIC % | -1072.47 | |||||
| ROC (Joel Greenblatt) % | -10370.64 | |||||
| ROCE % | -80.31 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.35 | |||||
| Price-to-Tangible-Book | 0.36 | |||||
| EV-to-EBIT | 1.04 | |||||
| EV-to-EBITDA | 1.04 | |||||
| EV-to-Forward-Revenue | 8.35 | |||||
| EV-to-FCF | 0.96 | |||||
| Price-to-Net-Current-Asset-Value | 0.36 | |||||
| Price-to-Net-Cash | 0.39 | |||||
| Earnings Yield (Greenblatt) % | 96.6 | |||||
| FCF Yield % | -215.3 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vivoryon Therapeutics NV Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.12 | ||
| Beta | 0.99 | ||
| Volatility % | 98.7 | ||
| 14-Day RSI | 22.46 | ||
| 14-Day ATR (€) | 0.120617 | ||
| 20-Day SMA (€) | 0.5088 | ||
| 12-1 Month Momentum % | -95.98 | ||
| 52-Week Range (€) | 0.41 - 19.56 | ||
| Shares Outstanding (Mil) | 25.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vivoryon Therapeutics NV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vivoryon Therapeutics NV Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vivoryon Therapeutics NV Frequently Asked Questions
What is Vivoryon Therapeutics NV(XAMS:VVY)'s stock price today?
The current price of XAMS:VVY is €0.57. The 52 week high of XAMS:VVY is €19.56 and 52 week low is €0.41.
When is next earnings date of Vivoryon Therapeutics NV(XAMS:VVY)?
The next earnings date of Vivoryon Therapeutics NV(XAMS:VVY) is 2024-04-24.
Does Vivoryon Therapeutics NV(XAMS:VVY) pay dividends? If so, how much?
Vivoryon Therapeutics NV(XAMS:VVY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers